<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2985">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01668901</url>
  </required_header>
  <id_info>
    <org_study_id>WASAK</org_study_id>
    <nct_id>NCT01668901</nct_id>
  </id_info>
  <brief_title>Warfarin Versus Aspirin in Patients With Atrial Fibrillation and Chronic Kidney Disease</brief_title>
  <official_title>A Randomized Controlled Prospective Trial of Warfarin Versus Aspirin for Stroke Prevention in Patients With Atrial Fibrillation and Chronic Kidney Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seoul National University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Seoul National University Hospital</source>
  <oversight_info>
    <authority>Korea: Food and Drug Administration</authority>
  </oversight_info>
  <brief_summary>
    <textblock>
      In this study, the investigators examine whether aspirin or warfarin is useful for atrial
      fibrillation patients with chronic kidney disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      randomised open labelled prospective study

      We enroll patients with CHADS2 score 1 non-valvular AF with chronic kidney disease, and
      analyze all thromboembolic event or major bleeding event during follow-up period. Warfarin
      group take dose adjusted warfarin (target INR 2.0-3.0) and aspirin group take aspirin 100mg
      daly.

      Thromboembolic events: Ischemic stroke or systemic arterial occlusion Major bleeding:
      gastrointestinal bleeding or intracranial bleeding (code 430, code 431, code 432 by ICD-9-CM
      codes)

      -&gt; Only the first event of each case will be used for the analysis
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">September 2015</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Thromboembolic event</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major bleeding</measure>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">720</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>warfarin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>aspirin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>warfarin</intervention_name>
    <arm_group_label>warfarin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>aspirin</intervention_name>
    <arm_group_label>aspirin</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  CHADS2 score 1 nonvalvular atrial fibrillation patients with chronic kidney disease

        Exclusion Criteria:

          -  HAS-BLED â‰¥30

          -  History of syncope or seizure within 1 year

          -  History of major bleeding event within 6 months

          -  BP&gt;180/100

          -  Abnormal prothrombin time

          -  Hypersensitivity of  aspirin or warfarin

          -  Folstein mini mental state examination score &lt;26

          -  Taking or had taken other anticoagulants
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Seil Oh, MD,PhD,FHRS</last_name>
    <phone>82-2-2072-2088</phone>
    <email>seil@snu.ac.kr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Myung-jin Cha, MD</last_name>
    <phone>82-10-9070-4090</phone>
    <email>chamj81@gmail.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Seoul Nationap University Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Seil Oh, MD, PhD,FHRS</last_name>
      <phone>82-2-2072-2088</phone>
      <email>seil@snu.ac.kr</email>
    </contact>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>August 2012</verification_date>
  <lastchanged_date>August 20, 2012</lastchanged_date>
  <firstreceived_date>August 16, 2012</firstreceived_date>
  <keyword>warfarin</keyword>
  <keyword>aspirin</keyword>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Atrial Fibrillation</mesh_term>
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
    <mesh_term>Kidney Failure, Chronic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Aspirin</mesh_term>
    <mesh_term>Warfarin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
